What Happened?
Cambridge, MA-based Foghorn Therapeutics Appointed Tara Maduri as Director, Accounting and Finance
About the Company
More than 20,000 genes make us human. Genes control critical aspects of health and disease — but what controls our genes? Foghorn® Therapeutics ($FHTX) is developing therapies based on a system that directs which genes our cells express, and when, where, and in what order. By manipulating this system with our unique Gene Traffic Control™ platform, Foghorn will change how genes turn “on” and “off.” Unlike approaches that edit genes, this novel way of thinking will alter what our DNA has in store for us—and rewrite destiny for millions of people living with disease. With Gene Traffic Control™ Foghorn is pioneering a new, major class of drug targets to develop unprecedented therapies for cancer and other serious diseases. We have already validated multiple targets, are in the process of developing drug candidates in multiple types of cancer and are beginning to explore other diseases.
About the Person
Tara Maduri is Director, Accounting and Finance at Foghorn Therapeutics. Previously, Tara held various senior HR leadership roles in the industry.
Info Source
News
Short Profile